Cryoport is celebrating the official opening of its most recent Global Logistics Center, based in Amsterdam, with a ribbon-cutting. The ceremony will be attended by Cryoport clients, governmental dignitaries and business partners. 

Cryoport’s “Chain of Compliance” processes will be employed at the new facility, which was built so that it can be rapidly scaled to support additional demand for services. Cryoport clients, including Gilead Sciences, Novartis, Bellicum Pharmaceuticals, Immatics, Janssen Pharmaceuticals, and others, will benefit from Cryoport’s new Global Logistics Center.

Amsterdam is a world-leading hub for the life sciences industry as a result of the region’s many cutting-edge researchers, startups and collaborations, favorable import and export environment, and significant transit infrastructure. 

Jerrell Shelton, chief executive officer of Cryoport, said, “The demand for comprehensive global support of regenerative therapies is growing rapidly. We are happy to add Amsterdam to our global network with its excellent connectivity and reputation as one of Europe’s leading life sciences hubs. Choosing this strategic locating for our newest Global Logistics Center allows us to more effectively support our global biopharmaceutical client base throughout the research, clinical and commercialization phases of their revolutionary regenerative therapies. We would also like to thank the Dutch regulatory officials who worked so effectively to accommodate and welcome us to Amsterdam.”